Navigation Links
R-Biopharm Group Purchases a Majority Ownership in Trilogy Lab, Expanding US Operations
Date:4/17/2010

R-Biopharm AG acquires a majority interest in Trilogy Analytical Laboratory

Darmstadt, Germany (PRWEB) April 17, 2010 -- R-Biopharm AG, a leading developer of test solutions for clinical diagnostics and food and feed safety, has announced today that the company has purchased a majority ownership position in Trilogy Analytical Laboratory, Inc. based in Washington, Missouri.

Founded in 1999, Trilogy Analytical is considered the premier commercial testing laboratory for the detection of mycotoxins and other contaminants for food and feed safety. Trilogy’s current facility has expanded into a 22,000 sq. ft. state of the art laboratory facility that employs 28 people. Trilogy’s analytical technology includes LC-MS-MS, HPLC and GC-MS. In addition, Trilogy offers a consumable product line that includes purification columns, chromatography standards and certified reference materials for use in the detection of mycotoxins.

“The management team and the senior technical staff will remain in place and Trilogy will continue to operate independently.” according to Dr. Ralf Dreher, Managing Director of R-Biopharm AG. “Trilogy’s name and reputation are synonymous with analytical excellence and the retention of Trilogy’s management team was mandatory for our long term strategic plans for expansion into the laboratory service business that will also support our diagnostic test kits. Trilogy is a welcome addition to the R-Biopharm Group”.

R-Biopharm AG currently has 13 subsidiary companies and distributes its products in more than 120 countries. R-Biopharm, Inc the US subsidiary will relocate and combine its facilities and operations with Trilogy in Washington, MO., although the two companies will continue to operate independently. “It’s important for Trilogy to maintain independence as a reference laboratory” said Kurt Johnson, President of R-Biopharm, Inc. “Even though R-Biopharm Group owns a majority interest in Trilogy they must maintain a level of trust and ensure confidentiality with their clients”.

“R-Biopharm’s commitment to allow us to continue to operate under the Trilogy brand and their engagement of our long term employees was instrumental in our decision to partner with R-Biopharm”, said Carrie Maune, President of Trilogy Analytical. “And although we had discussions with several other fine companies that had an interest in acquiring our business, the long term growth, expansion and independence of Trilogy was paramount in our decision process. R-Biopharm’s vast network of subsidiary companies and distributors will immediately expand our potential customer base worldwide”.

R-Biopharm is a leading developer of test solutions for clinical diagnostics and food & feed safety analysis. R-Biopharm assays offer high precision and accuracy, key requirements where patient, consumer and animal health are at risk. R-Biopharm has earned high accolades for its innovation and business performance. R-Biopharm’s industry leading technology has earned the company international recognition by being nominated as a finalist for 'Ernst & Young Entrepreneur of the Year in 2004, 2005, 2006 and 2009. R-Biopharm was also recognized in 2004 and 2005 after being placed in the 'Technology Text **

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3883244.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis
2. Summit Medical Group hosts “Go Red Day” to Raise Awareness of Heart Disease and Stroke
3. Emergo Group Acquires UK-based Mediqol Ltd.; Greatly Expands Medical Device Consulting Presence in Europe
4. Summit Medical Group Physician Named "Nurses Choice: Top Doctor"
5. Health, Conservation, Youth-Serving Groups To Surgeon General: Make Outdoor Time A Health Priority
6. Nuclear Medicine at Summit Medical Group Earns ACR Re-Accreditation
7. The Chicago Office of McDonald Hopkins Continues to Expand: Healthcare Attorney, Charles F. MacKelvie, Joins the Firms National Healthcare and Healthcare Restructuring Practice Groups
8. Government Executive Media Group Completes Leadership Search
9. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis
10. AT&T Launches Mobile Paging and Group Notification Solution for Healthcare Organizations
11. Public Health and Environmental Groups Support Stronger National Air Quality Standards for Ozone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: